Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 in Moderate-to-Severe Asthma (Phase II)
CTR20212563Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of stapokibart in asthma, sponsored by Keymed Biosciences. Started Oct 2021; status: completed.
02
Drugs
stapokibart
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20212563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212563.